Drugs / NAV5001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01950468 | Apr 2017 → Mar 2018 | parkinsonian disorder | Navidea Biopharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT01950455 | Nov 2013 → Jan 2018 | parkinsonian disorder | Navidea Biopharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00724906 | Jul 2010 → Jul 2011 | parkinsonian disorder | Alseres Pharmaceuticals, Inc | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NAV5001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01950455 ↗ |
| Known as | 123I-ALTROPANE | “all subjects receive a single intravenous (IV) injection of 123I-ALTROPANE® and single photon emission computed tomography (SPECT) imaging” NCT00724906 ↗ |
| Modality | Diagnostic / imaging agent | “radiopharmaceutical diagnostic imaging agent” NCT00724906 ↗ |
| Route | Intravenous | “administered intravenously” NCT00724906 ↗ |